Effects of bovine mammary secretion during the early nonlactating period and antibiotics on polymorphonuclear neutrophil function and morphology.
The effect of bovine mammary secretion during the early nonlactating period and of antibiotic preparations on bovine polymorphonuclear neutrophil (PMN) phagocytic function and morphology were evaluated in a series of in vitro multifactorial experiments. Benzathine cloxacillin (CL), benzathine cephapirin (CE), sodium novobiocin (NO), and a combination of dihydrostreptomycin with procaine penicillin G (DP) were prepared in the presence and absence of a peanut oil aluminum monostearate vehicle. The PMN were isolated from bovine blood, and the effect of each antibiotic preparation on PMN function and morphology was evaluated in a buffer, fat, skin, and a combination of fat with skim from bovine mammary secretion during the nonlactating period. The fat and skim were diluted with buffer to approximate their concentration in mammary secretion. Phagocytic functions of PMN were monitored by fluorescent microscopy, which made it possible to estimate both ingestion and intracellular killing of bacteria by PMN. Changes in PMN morphology were monitored by transmission electron microscopy. The ability of PMN to ingest and kill Staphylococcus aureus ATCC 25923 was significantly decreased by fat, skim, CL, CE, NO, and DP. Effects of some antibiotics on ingestion and killing of bacteria by PMN were influenced by the addition of vehicle and by interactions with mammary secretion. Neutrophil morphology was altered by fat, skim, CL, CE, NO, and DP. The detrimental effects of CL, CE, NO, and DP on PMN morphology were influenced (some significantly) by the presence of vehicle and interactions with mammary secretion. There were significant correlations among secretion- and antibiotic-induced changes in PMN ingestion of bacteria, PMN killing of bacteria, and PMN morphology.
Department of Veterinary Science, College of Agriculture, Pennsylvania State University, University Park 16875.
T J
TJ
Lintner
R J
RJ
Eberhart
D000818:Animals; D002417:Cattle; D002511:Cephalosporins / Q000494:pharmacology*; D002514:Cephapirin / Q000494:pharmacology*; D003023:Cloxacillin / Q000031:analogs & derivatives* / Q000494:pharmacology; D004096:Dihydrostreptomycin Sulfate / Q000494:pharmacology; D005260:Female; D007774:Lactation; D008321:Mammary Glands, Animal / Q000378:metabolism*; D008854:Microscopy, Electron; D009504:Neutrophils / Q000187:drug effects* / Q000502:physiology / Q000648:ultrastructure; D009675:Novobiocin / Q000494:pharmacology*; D010402:Penicillin G Procaine / Q000494:pharmacology; D010587:Phagocytosis / Q000187:drug effects*; D011247:Pregnancy; D013997:Time Factors
D002511:Cephalosporins; D009675:Novobiocin; D010402:Penicillin G Procaine; D002514:Cephapirin; C006692:benzathine cloxacillin; D003023:Cloxacillin; D004096:Dihydrostreptomycin Sulfate